- Home
- AZTR
AZTR
Azitra Inc
as 06-27-2025 1:30pm EST
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
| Founded: | 2014 | Country: | United States |
| Employees: | 12 | City: | BRANFORD |
| Market Cap: | 4.0M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.23 - $12.00 | Next Earning Date: | 08-11-2025 |
| Revenue: | $7,500 | Revenue Growth: | -98.69% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Azitra Inc News
AZTR Breaking Stock News: Dive into AZTR Ticker-Specific Updates for Smart Investing
PR Newswire
12 days ago
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
PR Newswire
19 days ago
Azitra, Inc. Announces Presentation at the 2025 BIO International Convention
PR Newswire
a month ago
Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
Zacks Small Cap Research
a month ago
AZTR: ATR-04 Trial to Dose 1st Patient Mid-2025
PR Newswire
a month ago
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash
PR Newswire
2 months ago
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
PR Newswire
2 months ago
Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025
PR Newswire
2 months ago
Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
Compare AZTR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AZTR Azitra Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.